Get the Stockscreener App
0.54
10.74%
-0.065
After Hours:
.56
0.02
+3.70%
Aspire Biopharma Holdings Inc stock is traded at $0.54, with a volume of 67,534.
It is down -10.74% in the last 24 hours and down -46.53% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.
See More
Previous Close:
$0.605
Open:
$0.572
24h Volume:
67,534
Relative Volume:
0.18
Market Cap:
$24.84M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-18.18%
1M Performance:
-46.53%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.54
$0.60
1-Week Range:
$0.54
$0.662
52-Week Range:
$0.52
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
1200 BROADWAY, FLOOR 3, NEW YORK
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.54 | 24.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
There is no way Aspire Biopharma Holdings Inc (ASBP) can keep these numbers up - SETE News
Sector Update: Health Care -March 20, 2025 at 01:41 pm EDT - MarketScreener
Aspire Biopharma Says Glatt Air Produces First Batch of Oral Mucosal Form of Aspirin -March 20, 2025 at 10:11 am EDT - Marketscreener.com
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin - standard-journal.com
Aspire Biopharma advances patent applications for drug delivery tech By Investing.com - Investing.com Australia
Aspire Biopharma advances patent applications for drug delivery tech - Investing.com India
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform - ACCESS Newswire
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation - The Kingston Whig-Standard
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement - wicz.com
Dykema Advises PowerUp Acquisition Corp. in Aspire Biopharma’s Nasdaq Listing - Dykema
Aspire Biopharma advances to phase 1 clinical trial for aspirin product - Investing.com India
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin - Corsicana Daily Sun
PowerUp Acquisition Corp. Approves Merger with Aspire Biopharma - MSN
Dow Tumbles Over 700 Points; US Services PMI Falls In February - Benzinga India
Aspire Biopharma Strengthens Financial Position with Debentures - TipRanks
Stock market news: Aspire Biopharma Holdings -51.46%, bluebird bio -39.20% among biggest losers during midday trading - Business Upturn
Stock market news: MicroAlgo skyrocketed by 480.87% whereas Mobile-health Network plunged by 42.65% during midday trading - Business Upturn
POWERUP ACQUISITION CORP. Submission of Matters to a Vote of Security Holders (form 8-K/A) - Marketscreener.com
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement - WICZ
Aspire Biopharma Goes Public with PowerUp Acquisition - TipRanks
ASBPAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
PowerUp Acquisition Completes Combination; Aspire Biopharma Gains Nasdaq Listing - Marketscreener.com
Aspire Biopharma begins trading on Nasdaq post-merger By Investing.com - Investing.com Nigeria
PowerUp Acquisition stock soars to all-time high of $15.15 - Investing.com India
Aspire Biopharma and PowerUp set merger terms, eye Nasdaq listing - Investing.com India
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp. - StockTitan
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
There is no financial data for Aspire Biopharma Holdings Inc (ASBP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):